Analysis method and system for noninvasive prenatal screening
By employing targeted high-depth sequencing technology and data processing methods, combined with global Z-test, forward-backward retrieval algorithm and Bayesian classifier, the challenges of detecting fetal chromosomal diseases and single-gene diseases in non-invasive prenatal screening have been solved, enabling accurate screening of various genetic diseases and reducing operational complexity and error rate.
Patent Information
- Application Number
- CN202411023315.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-29
AI Technical Summary
Current non-invasive prenatal screening technologies are insufficient to accurately detect the risk of fetal chromosomal disorders and single-gene diseases simultaneously, especially due to insufficient depth coverage of individual genes, making it impossible to comprehensively detect the risk of fetuses carrying single-gene diseases.
Targeted high-depth sequencing technology is used to obtain targeted high-depth sequencing data of target samples. Data preprocessing is performed to obtain depth information and SNP site information of the target region. Local microdeletion/microduplication analysis is performed using global Z-test and forward-backward retrieval algorithm. Combined with Bayesian classifier and SNP analysis, the final result is determined comprehensively.
It enables non-invasive prenatal screening for a variety of common fetal genetic diseases, reduces the complexity of experimental procedures, decreases the probability of sample errors, and improves the efficiency of clinical testing.
Smart Images

Figure BDA0004967884330000061 
Figure BDA0004967884330000071 
Figure BDA0004967884330000072
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of data processing, and in particular to an analysis method and system for non-invasive prenatal screening. Background Art
[0002] With the continuous development of high-throughput sequencing technology, whole-genome high-depth sequencing or targeted sequencing technology based on maternal plasma free DNA has been widely used in non-invasive prenatal screening. Initially, non-invasive prenatal screening mainly tested trisomy 21, 18, and 13 (non-invasive prenatal screening, NIPT), but has now been expanded to the detection of other chromosomal aneuploidies and microdeletions / microduplications, as well as non-invasive single-gene testing.
[0003] Non-invasive prenatal screening technology based on whole genome low-depth sequencing is mainly used to detect the risk of fetal chromosomal diseases, including aneuploidy and microdeletion / microduplication syndrome. However, due to the insufficient depth of coverage of a single gene, it is impossible to detect the risk of the fetus carrying a single gene disease. Non-invasive prenatal screening technology based on targeted high-depth sequencing can not only detect chromosomal diseases within the probe coverage range, but also can be used to detect the risk of fetal single gene diseases. Since the technical difficulty of detecting dominant single gene genetic diseases in the peripheral blood of pregnant women is relatively small, the currently disclosed technologies of this type can only screen chromosomal diseases and dominant single gene genetic diseases at the same time. The principle of using peripheral blood of pregnant women to detect new mutations in the fetus is that the mother herself is known to be wild type (genotype is represented by 00). If other alleles are detected in plasma DNA and the mutation frequency is significantly higher than the technical noise, it can be inferred that the site is a paternal or fetal new mutation (fetal genotype is represented by 01). Summary of the invention
[0004] The main purpose of the embodiments of the present invention is to propose an analysis method and system for non-invasive prenatal screening in order to solve at least one problem of the prior art. The present invention can comprehensively and accurately perform analysis of non-invasive prenatal screening.
[0005] To achieve the above object, one aspect of an embodiment of the present invention provides an analysis method for non-invasive prenatal screening, the method comprising:
[0006] Obtain targeted high-depth sequencing data of target samples;
[0007] Preprocess the targeted high-depth sequencing data to obtain the depth information and SNP site information of the targeted region; the depth information of the targeted region is the copy number information;
[0008] Based on the copy number information, the test results were obtained by global Z test;
[0009] Based on the copy number information, a forward-backward search algorithm is used to perform local microdeletion / microduplication analysis to obtain a first analysis result;
[0010] Based on the copy number information of the target region, the classification result is obtained by using a Bayesian classifier;
[0011] Based on the SNP site information, a second analysis result is obtained through SNP analysis;
[0012] The inspection result, the first analysis result, the classification result and the second analysis result are comprehensively judged to obtain the target analysis result.
[0013] In some embodiments, data preprocessing is performed on the targeted high-depth sequencing data to obtain depth information and SNP site information of the targeted region, including the following steps:
[0014] The sequencing depth and GC value of each probe were obtained based on targeted high-depth sequencing data;
[0015] The sequencing depth of the probes was normalized to obtain the copy number value;
[0016] A Lowess calibration curve is established according to the GC value and copy number of each probe, and then the copy number information of each probe is obtained based on the calibration result of the Lowess calibration curve;
[0017] The target SNP probe site is obtained based on the targeted high-depth sequencing data, and the allele combination and sequencing depth of each target SNP probe site are identified from the targeted high-depth sequencing data to obtain the SNP site information.
[0018] In some embodiments, based on the copy number information, a test result is obtained by a global Z test, comprising the following steps:
[0019] The targeted region of aneuploidy or microdeletion / microduplication syndrome was used as the unit of analysis;
[0020] Obtaining first copy number information of the analysis unit from the copy number information;
[0021] Obtain a preset number of negative samples as a reference sample library, and calculate the copy number mean and copy number standard deviation of each analysis unit in the reference sample library;
[0022] Based on the first copy number information, a Z-score value of the analysis unit corresponding to the copy number information is calculated in combination with the copy number mean and the copy number standard deviation;
[0023] The test result of the target sample is determined based on the Z-score value.
[0024] In some embodiments, based on the copy number information, a forward-backward search algorithm is used to perform local microdeletion / microduplication analysis to obtain a first analysis result, comprising the following steps:
[0025] Based on the target region sampled by the copy number information, multiple analysis windows are obtained by dividing each target region from left to right based on preset parameters; wherein the preset parameters include a set value of a window length of the analysis window or a set value of the number of probes in the analysis window;
[0026] Based on the copy number information, the copy number mean of all probes in each analysis window is obtained by statistics; the relative position of each analysis window in the entire targeted region is obtained;
[0027] Based on a preset retrieval seed threshold, sites whose absolute values of the mean screening copy numbers along the divided analysis window are greater than the retrieval seed threshold are used as retrieval seeds;
[0028] Traverse all the retrieval seeds, and when the positions of multiple retrieval seeds are continuous, merge the multiple retrieval seeds with continuous positions to obtain a seed block;
[0029] forward and backward search the adjacent windows of the seed block, calculate the average of the copy number corresponding to the adjacent window and the average of all copy numbers in the seed block, and obtain a first average value;
[0030] When the absolute value of the first average value is greater than a preset copy number threshold, the adjacent windows are merged into the corresponding seed block;
[0031] Traversing all seed blocks, when the distance between adjacent seed blocks is less than a preset distance threshold, calculating the mean of the copy numbers of the adjacent seed blocks to obtain a second average value;
[0032] When the absolute value of the second average value is greater than the copy number threshold, adjacent seed blocks are merged into a new seed block;
[0033] Based on all seed blocks remaining after merging, the relative positions were combined to determine the first analysis results of the local microdeletion / microduplication analysis for each targeted region.
[0034] In some embodiments, based on the copy number information of the target targeted region, a classification result is obtained by a Bayesian classifier, comprising the following steps:
[0035] The SEA region corresponding to the α gene is used as the analysis unit; the prior probability of severe thalassemia corresponding to the target sample and the DNA concentration of the target individual are obtained;
[0036] Based on all the copy number information in the SEA region, a Bayesian classifier model was established in combination with prior probability and DNA concentration, and then the classification results were obtained according to the Bayesian classifier model.
[0037] In some embodiments, based on the SNP site information, obtaining a second analysis result through SNP analysis comprises the following steps:
[0038] Based on the target region sampled by the copy number information, multiple analysis windows are obtained by dividing each target region from left to right based on preset parameters; wherein the preset parameters include a set value of a window length of the analysis window or a set value of the number of probes in the analysis window;
[0039] Based on the copy number information, the proportion of maternal genotypes and the proportion of maternal heterozygous genotypes in each analysis window are statistically obtained, and the copy number mean of all probes in each analysis window is statistically obtained; the relative position of each analysis window in the entire target region is obtained;
[0040] Based on the maternal genotype ratio and the maternal heterozygous genotype ratio in each analysis window, the forward-backward search algorithm is used to perform maternal chromosome deletion analysis and maternal copy number deletion analysis, respectively, to obtain the second analysis result.
[0041] In some embodiments, performing a comprehensive judgment on the inspection result, the first analysis result, the classification result, and the second analysis result to obtain a target analysis result includes the following steps:
[0042] determining a first result based on the test result;
[0043] When the test result is positive and both the first analysis result and the second analysis result are negative, the start and end positions of the targeted region corresponding to the positive result are used as the breakpoint positions of the copy number variation, thereby determining the second result;
[0044] Or, when the test result is positive, the first analysis result or the second analysis result is positive, the first analysis result or the second analysis result is used to correct the breakpoint position of the copy number variation, thereby determining the second result;
[0045] or, when the test result is negative, the positive result and the breakpoint position in the first analysis result or the second analysis result are used as the second result;
[0046] Perform hydrops fetal test on the classification results, and determine the third result according to the result of hydrops fetal test; the result of hydrops fetal test includes high risk of severe thalassemia or low risk of severe thalassemia;
[0047] A target analysis result is obtained according to the first result, the second result and the third result.
[0048] In some embodiments, the method for obtaining targeted high-depth sequencing data of a target sample comprises the following steps:
[0049] Extraction of cell-free DNA from peripheral blood samples of pregnant women;
[0050] Perform end repair, adapter ligation, PCR amplification of target fragments on free DNA, and construct sequencing library;
[0051] The DNA in the targeted region of the library is captured by hybridization capture technology, and high-depth sequencing is performed to obtain targeted high-depth sequencing data.
[0052] In some embodiments, the average sequencing depth in the high-depth sequencing is >500X.
[0053] To achieve the above object, another aspect of an embodiment of the present invention provides an analysis system for non-invasive prenatal screening, the system comprising:
[0054] Data acquisition module, used to obtain targeted high-depth sequencing data of target samples;
[0055] The data preprocessing module is used to preprocess the targeted high-depth sequencing data to obtain the depth information and SNP site information of the targeted region; the depth information of the targeted region is the copy number information;
[0056] A test module, used for obtaining a test result through a global Z test based on copy number information;
[0057] A first analysis module is used to perform local microdeletion / microduplication analysis based on copy number information using a forward-backward search algorithm to obtain a first analysis result;
[0058] A classification module, used to obtain classification results through a Bayesian classifier based on the copy number information of the target targeted region;
[0059] A second analysis module is used to obtain a second analysis result through SNP analysis based on the SNP site information;
[0060] The comprehensive determination module is used to make a comprehensive determination on the inspection result, the first analysis result, the classification result and the second analysis result to obtain a target analysis result.
[0061] To achieve the above objective, another aspect of an embodiment of the present invention provides an electronic device, the electronic device comprising a memory and a processor, the memory storing a computer program, and the processor implementing the above method when executing the computer program.
[0062] To achieve the above objective, another aspect of an embodiment of the present invention provides a computer-readable storage medium, wherein the computer-readable storage medium stores a computer program, and when the computer program is executed by a processor, the above method is implemented.
[0063] The embodiments of the present invention include at least the following beneficial effects: the present invention provides an analysis method and system for non-invasive prenatal screening, which obtains targeted high-depth sequencing data of target samples; performs data preprocessing on the targeted high-depth sequencing data to obtain depth information and SNP site information of the targeted region; the depth information of the targeted region is copy number information; based on the copy number information, the test result is obtained by global Z test; based on the copy number information, a forward-backward search algorithm is used to perform local microdeletion / microduplication analysis to obtain a first analysis result; based on the copy number information of the target targeted region, a classification result is obtained by a Bayesian classifier; based on the SNP site information, a second analysis result is obtained by SNP analysis; the test result, the first analysis result, the classification result and the second analysis result are comprehensively judged to obtain the target analysis result. The embodiments of the present invention can realize non-invasive prenatal screening of a variety of common genetic diseases of the fetus. It can effectively reduce the complexity of experimental operations, reduce the complexity of diagnostic processes, reduce the probability of sample errors caused by multiple sampling, significantly improve the efficiency of clinical tests, and have high practical value and application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0064] Figure 1 is a flow chart of an analysis method for non-invasive prenatal screening provided by an embodiment of the present invention;
[0065] Figure 2 This is a specific technical route of the analysis method for non-invasive prenatal screening provided by an embodiment of the present invention;
[0066] Figure 3 It is an optimization experiment for the number of reads fragments;
[0067] Figure 4 It is the distribution diagram of copy number and SNP statistics of Wolf-Hirschhorn syndrome positive cases;
[0068] Figure 5 It is the distribution graph of copy number and SNP statistics of Prader-Willi syndrome positive cases;
[0069] Figure 6 It is a distribution graph of copy number and SNP statistics of Angelman syndrome positive cases.
[0070] The copy number graph is a copy number distribution graph of the probes corresponding to the target regions for detecting Angelman syndrome (AS) and Prader-Willi syndrome (PWS). Each gray box is the result of a data subset enriched with fetal concentration. It can be seen that as the proportion of short fragment reads increases and the fetal concentration increases, the copy number of this region gradually decreases, which is consistent with the characteristics of deletion; SNP statistics are the statistical values of all SNP probes, and each gray box corresponds to a detected target region. Each point represents the snp.ratio value of a SNP probe; the purple line is the maternal genotype ratio of the probe in each analysis window of each SNP analysis window. i ; The yellow line is the ratio of maternal heterozygous genotypes in each analysis window maternal.het.ratio i In case 20, the purple line is close to 1, indicating that the mother's genotype accounts for 100% and does not carry the father's chromosome, that is, the paternal deletion; while in case 21, the purple line and the red line fluctuate within the error range, and no abnormality is detected. DETAILED DESCRIPTION
[0071] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. When the following description refers to the drawings, unless otherwise indicated, the same numbers in different drawings represent the same or similar elements. The embodiments described in the following exemplary embodiments do not represent all embodiments consistent with the embodiments of the present invention. They are only examples of systems and methods consistent with some aspects of the embodiments of the present invention as detailed in the attached claims.
[0072] It is understood that the terms "first", "second", etc. used in the present invention may be used herein to describe various concepts, but unless otherwise specified, these concepts are not limited by these terms. These terms are only used to distinguish one concept from another. For example, without departing from the scope of the embodiments of the present invention, the first information may also be referred to as the second information, and similarly, the second information may also be referred to as the first information. Depending on the context, the words "if" and "if" as used herein may be interpreted as "at the time of" or "when" or "in response to determining".
[0073] The terms "at least one", "multiple", "each", "any", etc. used in the present invention, at least one includes one, two or more, multiple includes two or more, each refers to each of the corresponding multiple, and any refers to any one of the multiple.
[0074] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used herein are only for the purpose of describing the embodiments of the present invention and are not intended to limit the present invention.
[0075] The analysis method for non-invasive prenatal screening provided by an embodiment of the present invention relates to the field of data processing technology. The analysis method for non-invasive prenatal screening provided by an embodiment of the present invention can be applied to a terminal, can be applied to a server, or can be software running in a terminal or a server. In some embodiments, the terminal can be a smart phone, a tablet computer, a laptop computer, a desktop computer, a smart speaker, a smart watch, and a car terminal, etc., but is not limited to this; the server side can be configured as an independent physical server, or a server cluster or distributed system composed of multiple physical servers, and can also be configured to provide cloud services, cloud databases, cloud computing, cloud functions, cloud storage, network services, cloud communications, middleware services, domain name services, security services, CDN, and big data and artificial intelligence platforms and other basic cloud computing services. The cloud server, the server can also be a node server in a blockchain network; the software can be an application of the analysis method for implementing non-invasive prenatal screening, etc., but is not limited to the above forms.
[0076] The present invention can be used in many general or special computer system environments or configurations. For example: personal computers, server computers, handheld or portable devices, tablet devices, multiprocessor systems, microprocessor-based systems, set-top boxes, programmable consumer electronic devices, network PCs, minicomputers, mainframe computers, distributed computing environments including any of the above systems or devices, etc. The present invention can be described in the general context of computer-executable instructions executed by a computer, such as program modules. Generally, program modules include routines, programs, objects, components, data structures, etc. that perform specific tasks or implement specific abstract data types. The present invention can also be practiced in distributed computing environments, in which tasks are performed by remote processing devices connected through a communication network. In a distributed computing environment, program modules can be located in local and remote computer storage media including storage devices.
[0077] Figure 1 is an optional flow chart of the analysis method for non-invasive prenatal screening provided by an embodiment of the present invention, Figure 1 The method may include but is not limited to steps S100 to S700, Figure 2 The specific technical route of the embodiment of the present invention;
[0078] S100, obtaining targeted high-depth sequencing data of target samples;
[0079] 1. Sample collection
[0080] Peripheral blood samples from 50 pregnant women whose fetal karyotype or genotype results were confirmed by prenatal diagnosis were collected, including 23 positive samples and 27 negative samples. All plasma samples were separated within 4 hours after collection. The sample information is shown in the following table:
[0081] Table 1
[0082]
[0083]
[0084] 2. Sample DNA extraction and library construction
[0085] Targeted high-depth library construction and sequencing: A tube of peripheral blood was collected from the pregnant woman, and the plasma was separated and the DNA was extracted; the library was constructed and the libraries of the same batch of hybridization were pooled; then hybridization was performed to capture the DNA in the targeted area of the library, and the library quality was checked after PCR. After the library quality inspection passed, high-depth sequencing was performed, and the average sequencing depth was >500X.
[0086] 1) Sample DNA extraction: Take one of the above sample types as an example and use nucleic acid extraction or purification reagents (Biomuhua Gene Technology Co., Ltd., catalog number: S10020). The method of large-volume cfDNA extraction was adopted, and the extraction process was optimized to adapt to the detection of this project. 2-3 ml of plasma was extracted from a single tube and a single sample at a time, so that the amount of DNA extracted from the sample reached the required volume for a single library construction without the need for subsequent concentration or purification.
[0087] 2) End repair and adapter ligation: Thermofisher Scientific's Ion Xpress Plus Fragment Library Kit was used to perform end repair and sequencing adapter ligation on the DNA fragments, and the products were purified using the Agencourt AMPure XP Kit. The reaction system is as follows:
[0088] Table 2 End repair reaction system
[0089]
[0090] Table 3 Sequencing adapter ligation reaction system
[0091]
[0092]
[0093] The linker used in this step is a linker primer containing A and P linkers with UID sequences designed by the inventors (for the specific sequence, see the patent document with application number CN201910565206.1); the introduction of UID can better remove point mutation errors introduced during the PCR process in sequencing, and errors caused by the polymerase itself can be removed; in addition, it can also be used to distinguish between the same gene sequences under natural conditions (pseudo-repeated sequences) and true repetitive sequences caused by PCR.
[0094] 3) Amplification before hybridization: The purified product in the previous step is amplified and enriched by PCR. The PCR system is as follows:
[0095] Table 4 PCR amplification reaction system
[0096]
[0097] The primer sequences are different for different sequencing platforms. The primers for the proton platform in this embodiment are as follows:
[0098] F:CCACTACGCCTCCGCTTTCCTCTCTATG; R:CCATCTCATCCCTGCGTGTC;
[0099] The PCR amplification products were purified using Agencourt AMPure XP Kit to obtain a DNA library for hybridization capture.
[0100] In this round of operation, plasma DNA was quantified using Qubit, and DNA library was quantified using qPCR. The results of some samples are shown in the following table:
[0101] Table 5
[0102]
[0103] 3. Probe capture and sequencing
[0104] 1) Probe capture: Use SureSelect TE Reagent Kit, PTN, 16 (Agilent) to hybridize the mixed DNA libraries in equal amounts according to the instructions, including blocking the libraries before hybridization, preparing the buffer working solution, preparing the probes designed in this patent into the probe mixed working solution, and adding the probes to the blocked DNA mixed library for hybridization capture at 67.5°C for 22 hours.
[0105] The regions targeted by the probes are as follows:
[0106] Table 6
[0107]
[0108] 2) Enrichment of the target region of the captured library: Dynabeads MyOne Streptavidin T1 (Invitrogen) was used to bind the captured library for 2-3 hours, and then the library bound to the T1 magnetic beads was eluted.
[0109] The cleaning steps are as follows:
[0110] Table 7
[0111]
[0112] Table 8
[0113]
[0114] 3) Post-PCR amplification: Dissolve the eluted and enriched T1 magnetic beads with 36.5 μL of nuclease-free water and perform PCR amplification according to the following system;
[0115] Table 9
[0116]
[0117] The PCR primer sequences are the same as those in Table 4. The PCR products were purified using the Agencourt AMPureXP Kit to obtain the products to be sequenced.
[0118] 4) Sequencing: The product to be sequenced is sequenced using the Ion Torrent platform, and the sequencing results are analyzed using bioinformatics. Targeted high-depth sequencing technology uses probes to capture free DNA in the targeted area and performs high-depth sequencing. The average depth of each site is usually not less than 100X. Exemplarily, in some specific embodiments, fetal multi-concentration gradient data can be first established to generate a gradient fetal concentration enrichment data set: using the feature that the length of fetal free DNA is significantly lower than that of maternal free DNA, different length screening thresholds (such as <168bp) can be set for the offline data of each sample, and short fragment reads can be screened to generate fetal multi-concentration gradient data, increasing the fetal concentration ratio by 1 to 3 times, effectively reducing the interference of maternal background. In the embodiment, 6 data sets with gradually increasing fetal concentrations were established, and the thresholds for reads screening were >178bp, all reads, <178bp, <168bp, <158bp, and <148bp, respectively. Generating a data set with gradually increasing fetal concentrations and analyzing whether the copy number of the chromosome or chromosome interval to be tested is consistent with the trend of fetal concentration changes helps to confirm the true positive sites.
[0119] S200, performing data preprocessing on the targeted high-depth sequencing data to obtain depth information and SNP site information of the targeted region;
[0120] Among them, the depth information of the targeted region is the copy number information;
[0121] It should be noted that, in some embodiments, step S200 may include: obtaining the sequencing depth and GC value of each probe based on the targeted high-depth sequencing data; normalizing the sequencing depth of the probe to obtain a copy number value;
[0122] A Lowess correction curve is established according to the GC value and copy number value of each probe, and the copy number information of each probe is obtained based on the correction result of the Lowess correction curve; the target SNP probe site is obtained based on the targeted high-depth sequencing data, and the allele combination and sequencing depth of each target SNP probe site are identified from the targeted high-depth sequencing data to obtain the SNP site information.
[0123] For example, in some specific embodiments, data preprocessing can be implemented as follows: (1) using BWA alignment software to align sequencing reads to the human reference genome (alignment parameters bwamem-t20-B1-O1-L1-TM reference), and remove duplicate sequences and low-quality alignment results; (2) statistically analyzing the depth information of the probes and performing data noise reduction: calculating the sequencing depth of each probe and performing normalization processing to remove the influence of the capture efficiency differences between probes, and then using the GC value of the probe (the molar percentage of guanine and cytosine to all bases in the whole genome DNA) and the normalized copy number value to establish a lowess correction curve, correct the influence of GC bias, and thereby obtain the copy number value of each probe. The copy number value of probe site i is recorded as copy.ratio i (3) The genotype information of the bi-allelic SNP probe sites was counted, and the allele combination and sequencing depth of each SNP site were identified using varscan software, and the frequency of the allele consistent with the human genome reference sequence (referred to as genotype A) was calculated (the genotype inconsistent with the human reference sequence was referred to as genotype B). The allele frequency of SNP site i was recorded as snp.ratio i .
[0124] S300, obtaining a test result through a global Z test based on the copy number information;
[0125] It should be noted that, in some embodiments, step S300 may include: taking the targeted region of aneuploidy or microdeletion / microduplication syndrome as an analysis unit; obtaining the first copy number information of the analysis unit from the copy number information; obtaining a preset number of negative samples as a reference sample library, and calculating the copy number mean and copy number standard deviation of each analysis unit in the reference sample library; based on the first copy number information, combining the copy number mean and the copy number standard deviation, calculate the Z-score value of the analysis unit corresponding to the copy number information; and determine the test result of the target sample based on the Z-score value.
[0126] Exemplarily, in some specific implementations, the global Z test can be implemented as follows:
[0127] Based on copy number information, chromosomal aneuploidy abnormalities and long-segment deletions / duplications are identified. The main analysis steps include: (1) The target region of aneuploidy or microdeletion / microduplication syndrome is used as the analysis unit, and the average copy number of all probes in each targeted region is calculated as the copy number value copy.ratio of the analysis unit. i . (2) Collect 200 negative samples as a reference sample library, and calculate the copy number mean and standard deviation of each analysis unit in the reference sample library. (3) Calculate the Z value (Z-score) of the analysis unit, and use the Z value to determine whether the sample has aneuploidy (the analysis unit covers the entire length of the chromosome, a Z value greater than 3 is judged as trisomy, and less than -3 is judged as monosomy) and long-segment deletions / duplications (the analysis unit covers a local area within the chromosome, a Z value greater than 3 is judged as microduplication, and less than -3 is judged as microdeletion). It should be noted that the breakpoint position of the deletion / duplication reported by the global Z test method is unclear, so the start and end positions of the probe targeting region are taken as the start and end points of the copy number variation by default. The Z-score calculation formula is:
[0128]
[0129] In the formula, copy.ratio i Indicates the copy number of the analysis unit, mean i represents the mean copy number, sd i represents the standard deviation of copy number;
[0130] S400, based on the copy number information, using a forward-backward search algorithm to perform local microdeletion / microduplication analysis to obtain a first analysis result;
[0131] It should be noted that, in some embodiments, step S400 may include: based on the target area sampled by the copy number information, dividing each target area from left to right based on preset parameters to obtain multiple analysis windows; wherein the preset parameters include a set value of the window length of the analysis window or a set value of the number of probes in the analysis window; based on the copy number information, statistically obtaining the copy number mean of all probes in each analysis window; obtaining the relative position of each analysis window in the entire target area; based on a preset retrieval seed threshold, screening sites along the divided analysis windows whose absolute value of the copy number mean is greater than the retrieval seed threshold as retrieval seeds; traversing all retrieval seeds, and when the positions of multiple retrieval seeds are continuous, traversing multiple retrieval seeds with continuous positions. The method comprises the following steps: merging the adjacent windows of the seed block to obtain a seed block; forward and backward searching the adjacent windows of the seed block, calculating the mean of the copy number corresponding to the adjacent window and the mean of all the copy numbers in the seed block to obtain a first average value; when the absolute value of the first average value is greater than a preset copy number threshold, merging the adjacent window into the corresponding seed block; traversing all the seed blocks, when the distance between adjacent seed blocks is less than a preset distance threshold, calculating the mean of the copy numbers of adjacent seed blocks to obtain a second average value; when the absolute value of the second average value is greater than the copy number threshold, merging the adjacent seed blocks into a new seed block; based on all the remaining seed blocks after merging, determining the first analysis result of the local microdeletion / microduplication analysis of each targeted region in combination with the relative position.
[0132] Exemplarily, in some specific embodiments, local microdeletion / microduplication analysis can be implemented as follows:
[0133] Based on the copy number information, combined with the forward-backward retrieval algorithm, the microdeletions / duplications within the chromosome and the targeted region are identified. The main analysis steps include: (1) Dividing the analysis window within the targeted region. Divide the targeted region corresponding to each disease into k analysis units from left to right. The division rule can choose a fixed window length or a fixed number of probes. The method of fixed number of probes is preferred so that the copy number error of each window is more stable; while the method of fixed window length will significantly increase the data fluctuation in the window with low probe density, which is not conducive to downstream data analysis. (2) Count the average copy number of all probes in each analysis window. (3) Use the forward-backward retrieval algorithm to identify the regions (blocks) of chromosome microduplication / microdeletion.
[0134] Specifically, the forward and backward retrieval algorithm is described in detail as follows:
[0135] Input data: the copy value copy.ratio of all windows in the entire target area and the corresponding relative position locs.
[0136] Algorithm parameters: retrieval seed threshold seed.cutoff; block copy number threshold block.cutoff; shortest seed length seed.block.min.len; shortest block length block.min.len; maximum distance max_distance allowed for merging adjacent blocks.
[0137] A. Initialize the search starting point. Use the preset search seed threshold (seed.cutoff) to select sites with an absolute copy number greater than the threshold as the search starting value, i.e. searching seeds.
[0138] B. Extend the search starting point to form searching seed.blocks. If the searched seed positions are continuous, merge them; traverse each possible starting point (seeds or seed.blocks) at the same time, and search for adjacent sites forward and backward. If the absolute value of the average copy number after merging adjacent sites is greater than the block copy number threshold (block.cutoff), the adjacent sites are included and seed.block is updated.
[0139] C. Use an iterative forward and backward search algorithm to find missing / duplicate blocks:
[0140] a) If there is a sufficiently long candidate region (searching.seed>seed.block.min.len), search the adjacent seed.blocks both forward and backward;
[0141] b) If the current block is adjacent to the previous block and meets certain conditions (distance < max_distance, and the absolute value of the copied value after merging > block.cutoff), the two blocks are merged to form a new seed.blocks;
[0142] c) Repeat steps a and b until the detection result remains unchanged, then add blocks to the blocks list.
[0143] S500, obtaining a classification result through a Bayesian classifier based on the copy number information of the target targeted region;
[0144] It should be noted that, in some embodiments, step S500 may include: taking the SEA region corresponding to the α gene as the analysis unit; obtaining the prior probability of severe thalassemia corresponding to the target sample and the DNA concentration of the target individual; based on all the copy number information in the SEA region, combining the prior probability and DNA concentration to establish a Bayesian classifier model, and then obtaining the classification result according to the Bayesian classifier model.
[0145] For example, in some specific implementations, the Bayesian classifier may be implemented as follows:
[0146] A Bayesian classifier model was established to calculate the probability of a fetus with severe thalassemia by combining the prior probability of severe thalassemia, fetal DNA concentration, and the copy number of the α-thalassemia gene region. The main analysis steps include: (1) The SEA region corresponding to the α gene was used as the analysis unit (referred to as the SEA region), and the average copy number of all probes in the SEA region was calculated as the copy number of the analysis unit. sea (2) Calculate the fetal DNA concentration fc of the sample and the prior probability of severe thalassemia. When both the father and mother of the fetus are SEA deletion carriers (missing two α-thalassemia genes), the fetus has three genotypes: normal, SEA deletion carrier and severe thalassemia (Bart's hydrops fetus, Hb Bart's), and their prior probabilities are 25%, 50% and 25%, respectively; (3) Use the multidimensional Bayesian probability model to calculate the Bayesian posterior probability P of the fetus being normal, SEA deletion carrier and severe α-thalassemia (Bart's hydrops fetus, Hb Bart's) genotype:
[0147]
[0148] Among them, A, B, and C represent normal, SEA deletion carrier, and major α-thalassemia genotypes, respectively; P A , P B and P C represents the prior probability of the three genotypes, which are set to 0.25, 0.5 and 0.25 respectively according to Mendel's law of inheritance; P (Ratio i |A,fc)、P(Ratio i |B,fc)、P(Ratio i |C,fc) indicates that under the condition of known current fetal DNA concentration fc and categories A, B, and C, the sample α-thalassemia gene copy number is Ratio i The probability of i ,fc) is the number of copies of α-thalassemia gene in the current sample to be tested, Ratio i , when the fetal concentration is fc, the sample category is C, that is, the probability of severe α-thalassemia. A threshold is set to judge samples with a probability value of severe thalassemia greater than 50% as severe thalassemia.
[0149] S600, obtaining a second analysis result through SNP analysis based on the SNP site information;
[0150] It should be noted that, in some embodiments, step S600 may include: based on the target area sampled by the copy number information, dividing each target area from left to right based on preset parameters to obtain multiple analysis windows; wherein the preset parameters include a set value for the window length of the analysis window or a set value for the number of probes in the analysis window; based on the copy number information, obtaining the maternal genotype ratio and the maternal heterozygous genotype ratio in each analysis window, and, obtaining the copy number mean of all probes in each analysis window; obtaining the relative position of each analysis window in the entire target area; based on the maternal genotype ratio and the maternal heterozygous genotype ratio in each analysis window, using a forward-backward retrieval algorithm to perform maternal chromosome deletion analysis and maternal copy number deletion analysis, respectively, to obtain a second analysis result.
[0151] It should be noted that the forward-backward retrieval algorithm is used to perform maternal chromosome deletion analysis on the maternal genotype ratio, and the forward-backward retrieval algorithm is used to perform maternal copy number deletion analysis on the maternal heterozygous genotype ratio. Correspondingly, the judgment conditions for the retrieval seeds and the merged seed blocks are set to be less than the preset corresponding thresholds. The process principle is the same and will not be repeated here.
[0152] For example, in some embodiments, SNP analysis can be performed as follows:
[0153] Integrating SNP genotype information can further identify the source of copy number variation, such as distinguishing Angelman syndrome (maternal chromosome segment deletion) from Prader-Willi syndrome (paternal chromosome segment deletion). The main analysis steps include: (1) Dividing the analysis window within the target region. Divide the target region corresponding to each disease from left to right into k analysis units. The division rule can choose a fixed window length or a fixed number of SNP probes. The method of fixing the number of SNP probes is preferred so that the error of the statistical value of each window is more stable. (2) Count the maternal genotype ratio of the probe in each analysis window. i and the ratio of heterozygous genotypes of the mother i (3) Average copy number average of all probes copy.ratio i (4) Use the forward-backward search algorithm in principle 4 to identify maternal.ratio i and maternal.het.ratio iThe abnormal regions where the maternal genotype ratio is significantly low are maternal chromosome deletion regions; the regions where the maternal heterozygous genotype ratio is low are maternal copy number deletion regions. (5) Distinguish between Angelman syndrome and Prader-Willi syndrome. When the sample is detected with 15q11.2-q13 deletion, if SNP analysis is used to find that there is a paternal deletion in this region, it is judged as Prader-Willi syndrome, otherwise it is judged as Prader-Willi syndrome.
[0154]
[0155] Among them, homo.probes.num i The total number of SNP sites indicating that the mother is homozygous (SNP condition: snp.ratio>0.8 or snp.ratio<0.2); homo.maternal.probes.num i Indicates the total number of SNP sites where the mother is homozygous and the paternal genotype is found in plasma (SNP condition: snp.ratio>0.98 or snp.ratio<0.02). i Indicates that non-maternal genotypes are not included in the analysis window (i.e., the mother is homozygous for genotype A but a low proportion of genotype B is detected in plasma, and the ratio of maternal.het.probes.num i Indicates the number of sites where the mother's genotype is heterozygous in the analysis window (SNP condition: snp.ratio ≥ 0.2 or snp.ratio ≤ 0.8); probes.num i Indicates the number of SNP probes in the analysis window.
[0156] S700, comprehensively determine the inspection result, the first analysis result, the classification result, and the second analysis result to obtain a target analysis result;
[0157] It should be noted that, in some embodiments, step S700 may include: determining a first result based on the test result; when the test result is positive and neither the first analysis result nor the second analysis result is positive, taking the starting and ending positions of the targeted area corresponding to the positive result as the breakpoint position of the copy number variation, and then determining the second result; or, when the test result is positive and the first analysis result or the second analysis result is positive, using the first analysis result or the second analysis result to correct the breakpoint position of the copy number variation, and then determining the second result; or, when the test result is negative, taking the positive result and the breakpoint position in the first analysis result or the second analysis result as the second result; performing a hydrops test on the classification result, and determining the third result according to the result of the hydrops test; the result of the hydrops test includes a high risk of severe thalassemia or a low risk of severe thalassemia; and obtaining the target analysis result according to the first result, the second result and the third result.
[0158] For example, in some specific implementations, the comprehensive determination may be implemented as follows:
[0159] The main rules of integrated analysis are as follows: (1) Detection of chromosome aneuploidy: the global Z test result shall prevail; (2) Detection of chromosome microdeletion and microduplication: when the global Z test is positive, if the microdeletion / microduplication analysis or SNP analysis is not positive, a positive result is issued and the start and end positions of the targeted region are used as the breakpoint positions of the copy number variation; when the global Z test is positive and the microdeletion / microduplication analysis result or SNP analysis is positive, the breakpoint position of the copy number variation is corrected using the results of the local variation analysis or SNP analysis; when the global Z test result is negative, the positive result of the traversal analysis or SNP analysis and the breakpoint position are output; (3) Detection of hydrops fetus: using the results of the Bayesian detection algorithm module, if the test result is positive, the fetus is considered to be at high risk of severe thalassemia, otherwise it is considered to be at low risk.
[0160] The table below shows the comparison of AOH test results based on SNP-mixed heterozygosity and chip-based SNP-array.
[0161] Among the 50 examples, 23 positive samples were detected with the chromosome type marked by the sample information, with a positive coincidence rate of 100%; severe thalassemia, chromosome aneuploidy and microdeletion / microduplication abnormalities were not detected in 27 negative samples, with a negative coincidence rate of 100%.
[0162] The embodiments establish fetal multi-concentration gradient data respectively, and generate fetal concentration enriched data subsets of 6 gradients (>178bp, all reads, <178bp, <168bp, <158bp, <148bp) for each sample. Each data subset can run the analysis process of the technical route respectively. As shown in the figure below, as the proportion of short fragment reads increases, the fetal concentration gradually increases, and the ratio value of the positive samples with copy number duplication gradually increases; the positive samples with copy number deletion decrease step by step. However, as the enrichment coefficient increases, the overall amount of available data decreases, resulting in poor data uniformity. Therefore, the present invention preferably uses the data subset of <158bp as the judgment result of the global Z test and the local deletion module ( Figure 3 ).
[0163] The test results of each positive sample in the embodiment are shown in the figure below. The test results of each sample include the results issued by the four detection modules and the final comprehensive judgment result. Comparing the comprehensive judgment result of the sample with the labeled information of the sample, the test result and the labeled information are 100% consistent.
[0164]
[0165]
[0166] For example, a positive case of Wolf-Hirschhorn syndrome is provided.
[0167] Case 17 is a positive sample for Wolf-Hirschhorn syndrome, and its copy number loss occurs in a local area within the targeted region. This sample cannot be detected as positive using the global Z test, and its copy number value is -1.949, and the Z value is -2.081, which fails to pass the positive threshold of the global test; the local microdeletion and microduplication analysis module automatically issues the result of local deletion in the chr4:185965-4737426 interval; in addition, the SNP analysis module indicates that there is a paternal deletion in the chr4:185989-5059668 interval. The results of the local microdeletion and microduplication analysis module and the SNP analysis module are consistent, so case 17 is finally determined to be Wolf-Hirschhorn syndrome ( Figure 4 ).
[0168] For example, a positive case of Prader-Willi syndrome and Angelman syndrome is provided.
[0169] Case 20 and case 21 samples are positive samples for Prader-Willi syndrome and Angelman syndrome, respectively. The deletion locations of these two syndromes are the same, so the copy number analysis method (including global Z test and local microdeletion / microduplication analysis module) can detect the deletion signal of the target region (chr15:22819714-28422634) (as shown below) Figure 5 and Figure 6 Copy number diagram), but failed to further distinguish between samples belonging to Prader-Willi syndrome and Angelman syndrome. Combined with the results of SNP analysis (case 20 carried a paternal deletion and case 21 did not carry a paternal deletion, see Figure 5 and Figure 6 The SNP statistical value distribution diagram in the figure can further determine that case 20 and case 21 are Prader-Willi syndrome and Angelman syndrome, respectively.
[0170] The embodiment of the present invention further provides an analysis system for non-invasive prenatal screening, which can implement the above-mentioned analysis method for non-invasive prenatal screening, and the system includes:
[0171] Data acquisition module, used to obtain targeted high-depth sequencing data of target samples;
[0172] The data preprocessing module is used to preprocess the targeted high-depth sequencing data to obtain the depth information and SNP site information of the targeted region; the depth information of the targeted region is the copy number information;
[0173] A test module, used for obtaining a test result through a global Z test based on copy number information;
[0174] A first analysis module is used to perform local microdeletion / microduplication analysis based on copy number information using a forward-backward search algorithm to obtain a first analysis result;
[0175] A classification module, used to obtain classification results through a Bayesian classifier based on the copy number information of the target targeted region;
[0176] A second analysis module is used to obtain a second analysis result through SNP analysis based on the SNP site information;
[0177] The comprehensive determination module is used to make a comprehensive determination on the inspection result, the first analysis result, the classification result and the second analysis result to obtain a target analysis result.
[0178] It can be understood that the contents of the above method embodiments are all applicable to the present system embodiments, the functions specifically implemented by the present system embodiments are the same as those of the above method embodiments, and the beneficial effects achieved are also the same as those achieved by the above method embodiments.
[0179] The embodiment of the present invention further provides an electronic device, the electronic device includes a memory and a processor, the memory stores a computer program, and the processor implements the above-mentioned non-invasive prenatal screening analysis method when executing the computer program. The electronic device can be any intelligent terminal including a tablet computer, a car computer, etc.
[0180] It can be understood that the contents of the above method embodiments are all applicable to the present device embodiments, the functions specifically implemented by the present device embodiments are the same as those of the above method embodiments, and the beneficial effects achieved are also the same as those achieved by the above method embodiments.
[0181] An embodiment of the present invention further provides a computer-readable storage medium, which stores a computer program. When the computer program is executed by a processor, the above-mentioned non-invasive prenatal screening analysis method is implemented.
[0182] It can be understood that the contents of the above method embodiments are all applicable to the present storage medium embodiments, the functions specifically implemented by the present storage medium embodiments are the same as those of the above method embodiments, and the beneficial effects achieved are also the same as those achieved by the above method embodiments.
[0183] The memory, as a non-transient computer-readable storage medium, can be used to store non-transient software programs and non-transient computer executable programs. In addition, the memory may include a high-speed random access memory, and may also include a non-transient memory, such as at least one disk storage device, a flash memory device, or other non-transient solid-state storage device. In some embodiments, the memory may optionally include a memory remotely disposed relative to the processor, and these remote memories may be connected to the processor via a network. Examples of the above-mentioned network include, but are not limited to, the Internet, an intranet, a local area network, a mobile communication network, and combinations thereof.
[0184] The analysis method and analysis system of non-invasive prenatal screening provided by the embodiment of the present invention obtain the targeted high-depth sequencing data of the target sample; perform data preprocessing on the targeted high-depth sequencing data to obtain the depth information and SNP site information of the targeted region; the depth information of the targeted region is the copy number information; based on the copy number information, the test result is obtained by the global Z test; based on the copy number information, the forward-backward search algorithm is used to perform local microdeletion / microduplication analysis to obtain the first analysis result; based on the copy number information of the target targeted region, the classification result is obtained by the Bayesian classifier; based on the SNP site information, the second analysis result is obtained by SNP analysis; the test result, the first analysis result, the classification result and the second analysis result are comprehensively judged to obtain the target analysis result. The embodiment of the present invention can realize non-invasive prenatal screening of a variety of common genetic diseases of the fetus. It can effectively reduce the complexity of experimental operations, reduce the complexity of diagnostic processes, reduce the probability of sample errors caused by multiple sampling, significantly improve the efficiency of clinical tests, and have high practical value and application prospects.
[0185] The embodiments described in the embodiments of the present invention are intended to more clearly illustrate the technical solutions of the embodiments of the present invention, and do not constitute a limitation on the technical solutions provided by the embodiments of the present invention. Those skilled in the art can appreciate that with the evolution of technology and the emergence of new application scenarios, the technical solutions provided by the embodiments of the present invention are also applicable to similar technical problems.
[0186] Those skilled in the art will appreciate that the technical solutions shown in the figures do not limit the embodiments of the present invention and may include more or fewer steps than shown in the figures, or a combination of certain steps, or different steps.
[0187] The system embodiments described above are merely illustrative, and the units described as separate components may or may not be physically separated, that is, they may be located in one place or distributed on multiple network units. Some or all of the modules may be selected according to actual needs to achieve the purpose of the present embodiment.
[0188] Those skilled in the art will appreciate that all or some of the steps in the methods disclosed above, and the functional modules / units in the systems and devices may be implemented as software, firmware, hardware, or a suitable combination thereof.
[0189] The terms "first", "second", "third", "fourth", etc. (if any) in the specification of the present invention and the above-mentioned drawings are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that the data used in this way can be interchanged where appropriate, so that the embodiments of the present invention described herein can be implemented in an order other than those illustrated or described herein. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions, for example, a process, method, system, product or device that includes a series of steps or units is not necessarily limited to those steps or units that are clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, products or devices.
[0190] It should be understood that in the present invention, "at least one (item)" refers to one or more, and "plurality" refers to two or more. "And / or" is used to describe the association relationship of associated objects, indicating that three relationships may exist. For example, "A and / or B" can represent: only A exists, only B exists, and A and B exist at the same time, where A and B can be singular or plural. The character " / " generally indicates that the previous and next associated objects are in an "or" relationship. "At least one of the following items" or similar expressions refers to any combination of these items, including any combination of single items or plural items. For example, at least one of a, b or c can represent: a, b, c, "a and b", "a and c", "b and c", or "a and b and c", where a, b, c can be single or multiple.
[0191] In the several embodiments provided by the present invention, it should be understood that the disclosed systems and methods can be implemented in other ways. For example, the system embodiments described above are only schematic. For example, the division of the above units is only a logical function division. There may be other division methods in actual implementation, such as multiple units or components can be combined or integrated into another system, or some features can be ignored or not executed. Another point is that the mutual coupling or direct coupling or communication connection shown or discussed can be through some interfaces, indirect coupling or communication connection of systems or units, which can be electrical, mechanical or other forms.
[0192] The units described above as separate components may or may not be physically separated, and the components shown as units may or may not be physical units, that is, they may be located in one place or distributed on multiple network units. Some or all of the units may be selected according to actual needs to achieve the purpose of the solution of this embodiment.
[0193] In addition, each functional unit in each embodiment of the present invention may be integrated into one processing unit, or each unit may exist physically separately, or two or more units may be integrated into one unit. The above-mentioned integrated unit may be implemented in the form of hardware or in the form of software functional units.
[0194] If the integrated unit is implemented in the form of a software functional unit and sold or used as an independent product, it can be stored in a computer-readable storage medium. Based on this understanding, the technical solution of the present invention, in essence, or the part that contributes to the prior art, or all or part of the technical solution can be embodied in the form of a software product. The computer software product is stored in a storage medium, including multiple instructions for a computer device (which can be a personal computer, a server, or a network device, etc.) to perform all or part of the steps of the methods of various embodiments of the present invention. The aforementioned storage medium includes: U disk, mobile hard disk, read-only memory (ROM), random access memory (RAM), disk or optical disk, etc., various media that can store programs.
[0195] The preferred embodiments of the present invention are described above with reference to the accompanying drawings, but the scope of the rights of the embodiments of the present invention is not limited thereby. Any modification, equivalent substitution and improvement made by those skilled in the art without departing from the scope and essence of the embodiments of the present invention shall be within the scope of the rights of the embodiments of the present invention.
Claims
1. A non-invasive prenatal screening analysis method, characterized in that: The method comprises the following steps: Obtain targeted high-depth sequencing data of target samples; Preprocessing the targeted high-depth sequencing data to obtain depth information and SNP site information of the targeted region; the depth information of the targeted region is copy number information; Based on the copy number information, a test result is obtained by a global Z test; Based on the copy number information, a forward-backward search algorithm is used to perform local microdeletion / microduplication analysis to obtain a first analysis result; Based on the copy number information of the target targeted region, a classification result is obtained by using a Bayesian classifier; Based on the SNP site information, obtaining a second analysis result through SNP analysis; A comprehensive judgment is performed on the inspection result, the first analysis result, the classification result and the second analysis result to obtain a target analysis result.
2. The method according to claim 1, characterized in that The method of performing data preprocessing on the targeted high-depth sequencing data to obtain depth information and SNP site information of the targeted region comprises the following steps: Obtaining the sequencing depth and GC value of each probe based on the targeted high-depth sequencing data; Normalizing the sequencing depth of the probe to obtain a copy number value; Establishing a Lowess calibration curve according to the GC value and the copy number value of each probe, and then obtaining the copy number information of each probe based on the calibration result of the Lowess calibration curve; The target SNP probe site is obtained based on the targeted high-depth sequencing data, and the allele combination and sequencing depth of each target SNP probe site are identified from the targeted high-depth sequencing data to obtain the SNP site information.
3. The method according to claim 1, characterized in that The method of obtaining a test result based on the copy number information by a global Z test comprises the following steps: The targeted region of aneuploidy or microdeletion / microduplication syndrome was used as the unit of analysis; Acquire first copy number information of the analysis unit from the copy number information; Obtaining a preset number of negative samples as a reference sample library, and calculating the copy number mean and copy number standard deviation of each analysis unit in the reference sample library; Based on the first copy number information, a Z-score value of the analysis unit corresponding to the copy number information is calculated in combination with the copy number mean and the copy number standard deviation; The test result of the target sample is determined based on the Z-score value.
4. The method according to claim 1, characterized in that The method of performing local microdeletion / microduplication analysis based on the copy number information using a forward-backward search algorithm to obtain a first analysis result comprises the following steps: Based on the target region sampled by the copy number information, a plurality of analysis windows are obtained by dividing each target region from left to right based on preset parameters; wherein the preset parameters include a set value of the window length of the analysis window or a set value of the number of probes in the analysis window; Based on the copy number information, the copy number mean of all probes in each analysis window is obtained by statistics; and the relative position of each analysis window in the entire target area is obtained; Based on a preset retrieval seed threshold, sites whose absolute values of the copy number means are greater than the retrieval seed threshold are selected along the analysis window as retrieval seeds; Traversing all the search seeds, when the positions of a plurality of the search seeds are continuous, merging the plurality of the search seeds with continuous positions to obtain a seed block; forward and backward search the adjacent windows of the seed block, and calculate the average of the copy number corresponding to the adjacent window and all the copy number averages in the seed block to obtain a first average value; When the absolute value of the first average value is greater than a preset copy number threshold, merging the adjacent windows into the corresponding seed block; Traversing all the seed blocks, when the distance between adjacent seed blocks is less than a preset distance threshold, performing mean calculation on the copy number means of the adjacent seed blocks to obtain a second average value; When the absolute value of the second average value is greater than the copy number threshold, merging the adjacent seed blocks into a new seed block; Based on all the seed blocks remaining after merging, the first analysis result of the local microdeletion / microduplication analysis of each of the targeted regions is determined in combination with the relative positions.
5. The method according to claim 1, characterized in that The method of obtaining a classification result based on the copy number information of the target targeted region by using a Bayesian classifier comprises the following steps: The SEA region corresponding to the α gene is used as an analysis unit; the prior probability of severe thalassemia corresponding to the target sample and the DNA concentration of the target individual are obtained; Based on all the copy number information in the SEA region, a Bayesian classifier model is established in combination with the prior probability and the DNA concentration, and then a classification result is obtained according to the Bayesian classifier model.
6. The method according to claim 1, characterized in that The method of obtaining a second analysis result by SNP analysis based on the SNP site information comprises the following steps: Based on the target region sampled by the copy number information, a plurality of analysis windows are obtained by dividing each target region from left to right based on preset parameters; wherein the preset parameters include a set value of the window length of the analysis window or a set value of the number of probes in the analysis window; Based on the copy number information, the maternal genotype ratio and the maternal heterozygous genotype ratio in each analysis window are statistically obtained, and the copy number mean of all probes in each analysis window is statistically obtained; the relative position of each analysis window in the entire target region is obtained; Based on the maternal genotype ratio and the maternal heterozygous genotype ratio in each analysis window, the forward-backward search algorithm is used to perform maternal chromosome deletion analysis and maternal copy number deletion analysis respectively to obtain the second analysis result.
7. The method according to claim 1, characterized in that The step of comprehensively judging the inspection result, the first analysis result, the classification result and the second analysis result to obtain a target analysis result comprises the following steps: determining a first result based on the test result; When the test result is positive and both the first analysis result and the second analysis result are negative, the start and end positions of the targeted region corresponding to the positive result are used as the breakpoint positions of the copy number variation, thereby determining the second result; Or, when the test result is positive, the first analysis result or the second analysis result is positive, the first analysis result or the second analysis result is used to correct the breakpoint position of the copy number variation, thereby determining the second result; Or, when the test result is negative, the positive result and the breakpoint position in the first analysis result or the second analysis result are used as the second result; Performing a hydrops fetus test on the classification result, and determining a third result according to the result of the hydrops fetus test; the result of the hydrops fetus test includes a high risk of severe thalassemia or a low risk of severe thalassemia; The target analysis result is obtained according to the first result, the second result and the third result.
8. The analysis method according to claim 1, characterized in that The method for obtaining targeted high-depth sequencing data of a target sample comprises the following steps: Extraction of cell-free DNA from peripheral blood samples of pregnant women; Perform end repair, adapter ligation, PCR amplification of target fragments on free DNA, and construct sequencing library; The DNA in the targeted region of the library is captured by hybridization capture technology, and high-depth sequencing is performed to obtain targeted high-depth sequencing data.
9. The analysis method according to claim 8, characterized in that The average sequencing depth in the high-depth sequencing is >500X.
10. A non-invasive prenatal screening analysis system, characterized in that: The system comprises: Data acquisition module, used to obtain targeted high-depth sequencing data of target samples; A data preprocessing module is used to perform data preprocessing on the targeted high-depth sequencing data to obtain depth information and SNP site information of the targeted region; the depth information of the targeted region is copy number information; A testing module, used for obtaining a test result through a global Z test based on the copy number information; A first analysis module, configured to perform local microdeletion / microduplication analysis based on the copy number information using a forward-backward search algorithm to obtain a first analysis result; A classification module, used for obtaining a classification result through a Bayesian classifier based on the copy number information of the target targeted region; A second analysis module, configured to obtain a second analysis result through SNP analysis based on the SNP site information; A comprehensive determination module is used to perform comprehensive determination on the inspection result, the first analysis result, the classification result and the second analysis result to obtain a target analysis result.
Citation Information
Patent Citations
Thalassemia detection kit and analysis system
CN110373458A
Method, kit and analysis system for synchronous prenatal screening of chromosomes and monogenic diseases
CN111951890A
Data processing method and device for noninvasive gene detection
CN114171118A
Method and detection system for screening copy number variation of hematologic tumor specimen based on next-generation sequencing technology
CN117316271A
Method, kit and system for synchronous prenatal detection of chromosomal aneuploidy and monogenic disease
US20230272473A1
Cited By
Kit, library construction method thereof and target variation detection and analysis method
CN119552946A
Preparation method of pregnant woman simulated plasma standard substance capable of enriching fetal concentration through fragment size
CN119799866A
A method for preparing a pregnant woman simulated plasma standard that can be enriched for fetal concentration by fragment size
CN119799866B
